Corporate
Compass Pathways Stock Surges 36% as Psilocybin Therapy COMP360 Hits 3-for-3 in Phase 3 Trials
Feb 17
You're signed outSign in or to get full access.
CP
COMPASS Pathways (CMPS)·Earnings Reports
Q3 2025
View earnings summary and analysis
Q2 2025
View earnings summary and analysis
Q1 2025
View earnings summary and analysis
Q4 2024
View earnings summary and analysis
Research analysts covering COMPASS Pathways.
